Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

SSW, PWRM, SGEN, SNT - Stock Alerts! from CRWEfinance.com - Seaspan, Power3 Medical Products, Seattle Genetics, senesco Technologies

|Includes: Seattle Genetics, Inc. (SGEN)

crwefinancelogo2

 

signup3m

 

 

___

  Power3 Medical Products, Inc. (OTC:PWRM)

PWRM, a bio-technology company, engages in the development and marketing of diagnostic tests in the fields of cancer, and neurodegenerative and neuromuscular diseases in the United States. PWRM's products include BC-SeraPro, a proteomic blood serum test for the early detection of breast cancer; and NuroPro, a serum test for the detection of neurodegenerative diseases, such as amyotrophic lateral sclerosis, Alzheimer's disease, and Parkinson's disease. PWRM's products analyze proteins and their mutations to assess an individual's risk for developing disease later in life or a patient's likelihood of responding to a particular drug; assess a patient's risk of disease progression and disease recurrence; and measure a patient's exposure to drug therapy. PWRM was formerly known as Surgical Safety Products, Inc. and changed its name to Power3 Medical Products, Inc. in September 2003. PWRM was founded in 1992 and is based in The Woodlands, Texas.

PWRM, a leading proteomics company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases, announced earlier this month that it delivered four poster presentations at the 2010 International Conference on Alzheimer's Disease (NASDAQ:ICAD) in Honolulu, Hawaii. These presentations discussed NuroPro, PWRM's diagnostic test, and focused on PWRM's Alzheimer's disease blood serum biomarkers, test and clinical validation trials.

PWRM has filed several patent applications for its NuroPro technology that are currently pending. PWRM also has a world-wide exclusive license from the Baylor College of Medicine in Houston, Texas. To date, PWRM has given 9 presentations on NuroPro at international scientific meetings in the United States, Europe and China, and has published 6 articles in peer-reviewed scientific journals on the subject. PWRM intends to publish these latest findings as well.

To learn more about PWRM visit: http://www.Power3Medical.com

*********************

  Delivery Technology Solutions, Inc. (OTCPK:DTSL)

DTSL is the leader in providing comprehensive custom-developed catering/delivery solutions to industries throughout North America, including restaurants, retail and others. DTSL's solutions offer a seamless system that integrates Customer Relationship Management (NYSE:CRM) and Call Center IT services through a proprietary technology backbone to offer convenience, consistent quality, flexibility, accountability and value for consumers and companies. DTSL was founded in 2010 and is based in Boca Raton, Florida.

DTSL, the leader in delivery management technology, has completed participation at one of the largest restaurant franchisee conventions, held July 22-25, 2010. Its UDS division attended the convention by invitation of the leading franchisor, and was able to showcase DTSL's large corporate catering and event management delivery technology platform to many of the thousands of convention attendees, and a range of other potential partners in the industry and associated industries.

The UDS Division is already planning for a larger role in next year's convention, due to the volume of responses expressed by this year's attendees, and the warm welcome that was received within the vendor community. While currently in expansion of its in-house sales and marketing department, UDS is expecting to implement up to 1,500 locations before the end of 2010, and many more in 2011.

 

To learn more about DTSL visit: http://www.universaldelivery.com

*********************

Seaspan Corporation (NYSE:SSW)

SSW announced recently that it has filed a universal shelf registration statement on Form F-3 with the United States Securities and Exchange Commission ("SEC"). The registration statement, which will replace an expired registration statement on Form F-3 that was previously filed with the SEC in April 2007, is intended to provide SSW with financial flexibility for future growth and does not reflect a change in its financing strategy. At present, SSW has no specific plans to issue securities under the registration statement.

SSW owns and operates the containerships that are engaged in the deep-sea container transportation business in Hong Kong. SSW charters its containerships pursuant to long-term, fixed-rate time charters to various container liner companies. As of December 31, 2009, SSW owned and operated a fleet of 42 containerships. SSW was incorporated in 2005 and is headquartered in Majuro, the Marshall Islands.

To learn more about SSW visit: http://www.seaspancorp.com

*********************

Seattle Genetics, Inc. (Nasdaq:SGEN)

Genmab A/S (OMX:GEN) & SGEN announced this month that the companies have entered into an antibody-drug conjugate (NYSE:ADC) research collaboration agreement. Under the agreement, Genmab has rights to utilize SGEN's ADC technology with its HuMax-TF antibody targeting the Tissue Factor antigen, which is expressed on numerous types of solid tumors. SGEN received an undisclosed upfront payment and has the right to exercise a co-development option for any resulting ADC products at the end of Phase I clinical development.

SGEN, a clinical-stage biotechnology company, focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. SGEN's lead product, SGN-35, is in pivotal trial for patients with relapsed or refractory hodgkin lymphoma. SGEN also has an antibody-drug conjugates co-development agreement with Agensys, Inc. SGEN was founded in 1997 and is headquartered in Bothell, Washington.

To learn more about SGEN visit: http://www.seattlegenetics.com

*********************

Senesco Technologies, Inc. (Amex:SNT)

SNT participated in the Rodman & Renshaw 12th Annual Global Investment Conference that was held at the Palace Hotel in New York City. Leslie J. Browne, Ph.D., Senesco’s President & CEO, deliver SNT’s corporate presentation.

SNT, a development stage biotechnology company, focuses on the development of technologies to treat programmed cell death diseases in humans. SNT's technologies are also used to enhance the productivity of fruits, flowers, vegetables, forestry species, and agronomic crops through the control of cell death in plants. SNT was founded in 1964 and is headquartered in New Brunswick, New Jersey.

To learn more about SNT visit: http://www.senesco.com

___

 

 

********************************************************************

http://crwefinance.com/img/crwefinance_new_buscard2.jpg

Signup for FREE Daily Stock Alerts From CRWEFinance.com/signup 

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEFinance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEFinance.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://crwefinance.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE) has previously received five hundred thousand shares as compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (OTC:PWRM). Recently, Crown Equity Holdings Inc. had received an additional amount of 2,000,000 shares of free trading stock for 60 days of media advertisement, web design and maintenance for Power 3 Medical Products Inc. (OTC:PWRM). Each advertising commitment has now expired. Crown Equity Holdings Inc. (OTCPK:CRWE) has received twenty-five thousand dollars in cash from a third party (Ceiba Network/PenStox) for (30) days of advertising for Delivery Technology Solutions, Inc. (OTCPK:DTSL)